Tolerance and Cancer: A Critical Issue in Tumor Immunology

Critical Reviews in Oncogenesis

Volumn 7, Issue 5-6, 1996, Pages 433-456

  Sotomayor, Eduardo M ^a   Borrello, Ivan ^a   Levitsky, Hyam I ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anergy; Antigen specific tolerance; Clonal deletion; Clonal diversion; Immunosuppression

Indexed keywords

ANTIGEN SPECIFICITY; CANCER IMMUNOLOGY; CANCER RESISTANCE; CLONAL ANERGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; LYMPHOCYTES; MICE; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 0030319698     PISSN: 08939675     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevOncog.v7.i5-6.30     Document Type: Article

References (167)

1. Allison, J. P.: CD28-B7 interactions in T cell activation. Curr. Opin. Immunol., 6:414-419 (1994).
2. Allison, J. P., A. A. Hurwitz, and D. R. Leach: Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr. Opin. Immunol., 7:682-686 (1995).
3. Amakawa, R., A. Hakem, T. M. Kundig, T. Matsuyama, J. J. Simard, E. Timms, A. Wakeham, H. W. Mittruecker, H. Griesser, H. Takimoto, R. Schmits, A. Shahinian, P. Ohashi, J. M. Penninger, and T. W. Mak: Impaired negative selection of T cells in Hodgkin's disease antigen CD-30-deficient mice. Cell, 84:551-562 (1996).
4. Awwad, M. and R. J. North: Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant routine tumor: a consequence of eliminating precursor L3T4 + suppressor T cells. Cancer Res., 49:1649-1654 (1989).
5. Azuma, M., M. Cayabyaab, J. H. Phillips, and L. L. Lanier: Requirements for CD28-dependent T cell-mediated cytotoxicity. J. Immunol., 150:2091-2101 (1993).
6. Baskar, S., S. Ostrand-Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class D molecules. Proc. Natl. Acad. Sci. U.S.A., 90:5687-5690 (1993).
7. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med., 181:619-629 (1995).
8. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzussoff, and R. C. Duke: A role for CD95 ligand in preventing graft rejection. Nature, 377:630-632 (1995).
9. Beverly, B., S-M. Kang, M. J. Lenardo, and R. H. Schwartz: Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol., 4:661-671 (1992).
10. Bhatia, R., P. B. McGlave, G. W. Dewald, B. R. Blazar, and Verfaillie: Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: role of malignant stromal macrophages. Blood, 85:3636-3645 (1995).
11. Billingham, R. E, L. Brent, and P. B. Medawar: Quantitative studies on tissue transplantation immunity. III. Actively acquired tolerance. Phil. Trans. Roy. Soc. (London), Ser. B. 239:357-414 (1956).
12. Billingham, R. E., L. Brent, and P. B. Medawar: Actively acquired tolerance of foreign cells. Nature, 172:603-606 (1953).
13. Bluestone, J. A.: Is CTLA-4 a master switch for peripheral T cell tolerance? J. Immunol., 158:1989-1993 (1997).
14. Bogen, B.: Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4 + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur. J. Immunol., 26:2671-2679 (1996).
15. Boon, T. and P. van der Bruggen: Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183:725-729 (1996).
16. Boussiotis, V. A., D. L. Barber, T. Nakarai, G. J. Freeman, J. G. Gribben, G. M. Bernstein, A. L. D'Andrea , J. Ritz, and L. M. Nadler: Prevention of T cell anergy by signaling through the 70 chain of the IL-2 receptor. Science, 266:1039-1042 (1994).
17. Brent, L.: Landmarks in immunology. In: A History of Transplantation Immunology. Academic Press, London, UK, 1-55 (1997).
18. Bretscher, P. and M. Cohn: A theory of self-non-self discrimination: paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science, 169:1042-1049 (1970).
19. Broder, S. and A. Waldmann: The suppressor-cell network in cancer. N. Engl. J. Med., 299:1281-1284 (1978).
20. Brunet, J. F., F. Denizot, M. F. Luciani, M. Roux-Dosseto, M. Suzan, M. G. Mattei, and P. Golstein: A new member of the immunoglobulin superfamily - CTLA-4. Nature (London), 328:267-270 (1987).
21. Burnet, F. M. and F. Fernner: The Production of Antibodies. 2nd ed., MacMillan, Melbourne, London (1949).
22. Calderon, C., Z. Huang, D. A. Gage, E. M. Sotomayor, and D. M. Lopez: Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidilserine. J. Exp. Med., 180:945-958 (1994).
23. Cardoso, A. A., J. L. Schultze, V. A. Boussiotis, G. J. Freeman, M. J. Seamon, S. Laszlo, A. Billet, S. E. Sallan, J. G. Gribben, and L. M. Nadler: Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood, 88:41-48 (1996).
24. Chambers, C. A. and J. P. Allison: Co-stimulation in T cell responses. Curr. Opin. Immunol., 9:396-404 (1997).
25. Chen, L., P. McGowan, S. Ashe, J. Johnston, Y. Li, I. Hellstrom, and K. E. Hellstrom: Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J. Exp. Med., 179:523-532 (1994).
26. Chen, L., S. Ashe, W. A. Brady, I. Hellstrom, K. E. Hellstrom, J. A. Ledbetter, P. McGowan, and P. S. Linsley: Costimulation of antitumor irnmunity by the B7 counter-receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71:1093-1102 (1992).
27. Cho, E. A., M. P. Riley, A. L. Sillman, and H. Quill: Altered protein tyrosine phosphorylation in anergic Th1 cells. J. Immunol., 151:20-28 (1993).
28. Clerici, M. and G. M. Shearer: The Thl-Th2 hypothesis of HTV infection: new insights. Immunol. Today, 15:575-581 (1994).
29. Cohen, P. L. and R. A. Eisenberg: LPR and OLD: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol., 9:243-270 (1991).
30. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. Mulligan: Vaccination with irradiated tumor cells engineered to secrete murine GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.SA., 90:3539-3543 (1993).
31. Doyle, A., W. J. Martin, K. Funa, D. Gazdar, S. E. Carney, I. Martin, F. Linnoila, F. Cuttita, J. Mulshoine, P. Bunn, and J. Minna: Markedly decreased expression of class I histocompatibility antigens, protein and mRNA on human small-cell lung cancer. J. Exp. Med., 161:1135-1151 (1985).
32. + T cells. Science, 271:1276-1278 (1996).
33. Finke, J., H. Zea, J. Stanley, D. L. Longo, H. Mizoguchi, R. Tubbs, R. Wiltrout, J. O'Shea, J. Kudoh, S. Klein, E. Bukowski, and A. C. Ochoa: Loss of T cell receptor ζ chain and p56 in T cells infiltrating human renal cell carcinoma. Cancer Res., 53:5613-5616 (1993).
34. Florentine, D. F., A. Zlotnik, T. R. Mossmann, M. Howard, and A. O'Garra: IL-10 inhibits cytokine production by activated macrophages. J. Immunol., 147:3815-3822 (1991).
35. Fowlkes, B. J. and D. M. Pardoll: Molecular and cellular events of T. cell development. Adv. Immunol., 44:207-264 (1989).
36. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. Restivo, L. Lombard, G. S. Gray, and L. M. Nadler: Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation. Science, 262:909-911 (1993a).
37. Freeman, G. J., F. Borriello, R. J. Modes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnight, J. Kim, L. Du, D. B. Lombard, G. S. Gray, L. M. Nadler, and A. H. Sharpe: Uncovering of functional alternative CTLA4 counter-receptor in B7-deficient mice. Science, 262:907-909 (1993b).
38. Fuchs, E. J. and P. Matzinger: B cells turn off virgin but not memory T cells. Science, 258:1156-1159 (1992).
39. Gabrilovich, D. I., I. F. Ciernik, and D. P. Carbone: Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol., 170:101-110 (1996).
40. Gajewsky, T. F. and F. W. Fitch: Anti-proliferative effect of IFN-y in immune regulation I. IFN-gamma inhibits the proliferation of Th2 but not Thl murine helper T lymphocytes clones. J. Immunol., 140:4245-4252 (1988).
41. Gershon, R. K. and K. Kondo: Infectious immunological tolerance. Immunology, 21:903-914 (1971).
42. Gerson, J. M., L. Varesio, and R. B. Herberman: Systemic and in situ natural killer and suppressor cell activities in mice bearing progressively growing murine sarcoma-virus-induced tumors. Int. J. Cancer, 27:243-248 (1981).
43. Ghosh, P., K. L. Komschlies, M. Cippitelli, D. L. Longo, J. Subleski, J. Ye, A. Sica, H. A. Young, R. H. Wiltrout, and A. C. Ochoa: Gradual loss of T-helper 1 populations in spleen s of mice with progressive tumor growth. J. Natl. Cancer Inst., 87:1478-1483 (1995).
44. Gimmi, C. D., G. J. Freeman, J. G. Gribben, K. Sugita, A. S. Freedman, C. Morimoto, and L. M. Nadler: B7 provides a costimulatory signal which induces stimulated T cells to proliferate and secrete interleukin-2. Proc. Natl. Acad. Sci. U.S.A., 88:6575-6579 (1991).
45. Gong, J., D. Chen, M. Kashiwaba, and D. Kufe: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med., 3:558-561 (1997).
46. Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, Jr., and-R. A. Flavell: Requirement for CD40 ligand in co-stimulation induction, T cell activation, and experimental allergic encephalomyelitis. Science, 273:1864-1867 (1996).
47. Griffith, T. S., T. Brunner, S. Fletcher, D. R. Green, and T. A. Ferguson: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270:1189-1192 (1995).
48. Guerder, S., J. Meyerhoff, and R. Flavell: The role of the T cell costimulator B 7-1 in autoimmunity, and the induction and maintenance of tolerance to peripheral antigen. Immunity, 1:155-166 (1994).
49. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J-C. Cerottini, and J. Tschopp: Melanoma cell expression of Fas (Apo-1/CD95)ligand: implications for tumor immune escape. Science, 274:1363-1366 (1996).
50. Handel-Fernandez, M. E., X-F. Cheng, L. M. Herbert, and D. M. Lopez: Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mamary tumorbearing mice J. Immunol., 158:280-286 (1997).
51. Hording, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison: CD28-raediated signalling co-stimulates murine T cells and prevents induction of anergy in T cell clones. Nature, 356:607-609 (1992).
52. Harding, F. A. and J. P. Allison: CD28-B7 interactions allow the induction of CDS + cytotoxic T lymphocytes in the absence of exogenous help. J. Exp. Med., 177:1791-1796 (1993).
53. Heinzel, F. P., M. D. Sadick, B. J. Holaday, R. L. Coffman, and R. M. Locksley: Reciprocal expression of interferon-γ; on interleukin-4 during the resolution and progression of murine leishmaniasis. J. Exp. Med., 169:59-72(1989).
54. Hodge, J. W., S. Abrams, J. Schlom, and J. A. Kantor: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res., 54:5552-5555 (1994).
55. Houghton, A. N.: Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180:1-4 (1994).
56. Hsu, F., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidoi, E. G. Engleman, and R. Levy: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med., 2:52-58 (1996).
57. Huang, A., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky: Role of bone marrow-derived cells in presenting MHC class-I-restricted tumor antigens. Science, 264:961-965 (1994).
58. Huang, A., A. Bruce, D. Pardoll, and H. I. Levitsky: Does B7-1 expression confer antigen presenting cell capacity to tumors in vivo? J. Exp. Med., 183:769-776 (1996).
59. Huber, D., J. Philipp, and A. Fontana: Protease inhibitors interfere with the transforming growth factor β-dependent but not the TGF β-independent pathway of tumor cell-mediated immunosuppression. J. Immunol., 148:277-284 (1992).
60. Jenkins M. K. and R. H. Schwarte: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med., 165:302-319 (1987a).
61. Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, T. M. Chused, and R. H. Schwartz: Molecular events in the induction of a nonresponsive state in interleukm-2-producing helper T-lymphocyte clones. Proc. Natl. Acad. Sci. U.S.A., 84:5409-5413 (1987b).
62. + cytolytic T lymphocytes. J. Exp. Med., 183:791-800 (1996).
63. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson: The B7 and CD28 receptor families. Immunol. Today, 15:321-331 (1994).
64. Kagi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagat, H. Hengartner, and P. Golstein: Fas and perform pathways as major mechanisms of T-cell-mediated cytotoxicity. Science, 265:528-530 (1994).
65. Kang, S-M., B. Beverly, A-C. Tran, K. Brorson, R. H. Schwartz, and M. J. Lenardo: Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science, 257:1134-1138 (1992).
66. Kappler, J. W., N. Roehm, and P. Marrack: T cell tolerance by clonal elimination in the thymus. Cell, 49:273-280 (1987).
67. Kappler, J. W., U. Staerz, J. White, and P. Marrack: Self-tolerance eliminates T cells specific for Mis-modified products of the major histocompatibility complex. Nature, 332:35-40 (1988).
68. Karandikar, N. J., C. L. Vanderlugt, T. L. Walunas, S. D. Miller, and J. A. Bluestone: CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med., 184:783-788 (1996).
69. + cells in Staphylococcus enterotoxin B-primed mice. J. Exp. Med., 172:1069-1078 (1990).
70. Kearney, B. R., K. A. Pape, D. Y. Loh, and M. K. Jenkins: Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity, 1:327-329 (1994).
71. Kisielow, P., H. S. Teh, H. Bluthmann, and H. von Boehmer: Positive selection of antigen specific T cells in thymus by restricting MHC molecules. Nature, 335:730-733 (1988).
72. Kono, K., F. Salazar-Onfray, M. Petersson, J. Hansson, G. Masucci, K. Wasserman, T. Nakazawa, P. Anderson, and R. Kiessling: Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur. J. Immunol., 26:1308-1313 (1996).
73. Krummel, M. F. and J. P. Allison: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med., 182:459-465 (1995).
74. Lafferty, K. J. and A. J. Cunningham: A new analysis of allogenic interactions. Aust. J. Exp. Biol. Med. Sci., 53:27-42 (1975).
75. Leach, D. R., M. F. Krummel, and J. P. Allison: Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271:1734-1736 (1996).
76. Lenschow, D. J., Y. Zeng, J. R. Thistlewaite, Mont, Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science, 257:789-792 (1992).
77. Lenschow, D. J., A. L Sperling, M. P. Cooke, G. Freeman, L. Rhee, D. C. Decker, G. Gray, L. M. Nadler, C. C. Goodnow, and J. A. Bluestone: Differential up-regulation of the B7-1 and B7-2 co-stimulatory molecules after Ig receptor engagement by antigen. J. Immunol., 153:1990-1997 (1997).
78. Levitsky, H. I.: Tumors derived from antigen-presenting cells. Semin. Immunol., 8:281-287 (1996a).
79. Levitsky H. I., J. Montgomery, M. Ahmadzadeh, K. Staveley-O'Carrol, F. Guarnieri, D. L. Longo, and L. W. Kwak: Immunization with granulocyte-macrophage colonystimulating factor-transduced, butnotB7-l transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol., 156:3858-3865 (1996b).
80. Li, W., C. D. Whaley, A. Mondino, and D. L. Mueller: Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science, 271:1272-1276 (1996).
81. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol., 153:421-428 (1994).
82. Liblau, R. S., R. Tisch, K. Shokat, X-D. Yang, N. Dumont, C. C. Goodnow, and H. O. McDevitt: Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis. Proc. Natl. Acad. Sci. U.S.A., 93:3031-3036 (1996).
83. Lillie, E. R.: The theory of the Free-Martin. Science, 43:611-613 (1916).
84. Linsley, P. S., W. Brady, L. Grosmaire, A. Aruffo, N. K. Damle, and J. A. Ledbetter: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin-2 mRNA accumulation. J. Exp. Med., 173:721-730 (1991a).
85. Linsley, P. S., W. Brady, M. Urnes, L. S. Grosmaire, N. K. Damle, and J. A. Ledbetter: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med., 174:561-569 (1991b).
86. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper: Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science, 257:792-795 (1992).
87. Lo, D., L. C. Burkly, G. Widera, C. Cowing, R. A. Flavell, R. D. Palmiter, and R. L. Brinster: Diabetes and tolerance in transgenic mice expressing class n MHC molecules in pancreatic beta cells. Cell, 53:159-168 (1988).
88. Lopez, D. M., R. R. Padmanabhan, L. M. Rivera, R. D. Paul, L. Herbert, C. Cray, and G. A. Watson: Cytotoxic effector mechanisms involved in the immunity against mam- mary tumors. In: Breast Cancer: Scientific and Clinical Progress (M. A. Rich, J. C. Hager, and D. M. Lopez, Eds.) Boston, Kluwer Academic Publishers, p. 185 (1988).
89. Lopez, D. M., M. E. Handel-Fernandez, X-F. Cheng, V. Charyulu, L. Herbert, M. R. Dinapoli, and C. L. Calderon: Cytokine production by lymphoreticular cells from mammary tumor bearing mice: the role of tumor-derived factors. Anticancer Res., 16:3923-3930 (1996).
90. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp: Cytolytic T cell-cytotoxicity is mediated through perform and Fas lytic pathways. Nature, 370:650-652 (1994).
91. a-encoded antigen. Nature, 332:40-45 (1988).
92. Mamula M. J. and C. A. Janeway: Do B cells drive the diversification of immune responses? Immunol. Today, 14:151-152 (1993).
93. Marrack, P., D. Lo, R. Brinster, R. Palmitter, L. Burkly, R. H. Flavell, and J. Kappler: The effect of thymus environment on T cell development and tolerance. Cell, 53:627 (1988).
94. McDonald H. R., S. Baschieri, and R. K. Lees: Clonal expansion precedes anergy and death of Vb 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur. J. Immunol., 21:1963-1966 (1991).
95. Miescher, S., T. L. Whiteside, S. Carrel et al.: Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferation responses of lymphocytes. J. Immunol., 136:1899-1903 (1986).
96. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa: Alterations in signal transduction molecules m T lymphocytes from tumor bearing mice. Science, 258:1795-1798 (1992).
97. Mondino, A., C. D. Whaley, D. R. DeSilva, W. Li, M. K. Jenkins, and D. L. Mueller: Defective transcription of the IL-2 gene is associated with impaired expression of c-Fos, Fos B, and JunB in anergic T helper 1 cells. J. Immunol., 157:2048-2057 (1996).
98. Morahan, G., J. Allison, and J. F. A. P. Miller: Tolerance of class I histocompatibility antigens expressed extrathymically. Nature, 339:622-624 (1989).
99. Moser, G., M. G. Kauffman, and A. K. Abbas: Accesory cells in immune suppression. II. Evidence for presentation of idiotype-specific suppressor factors to B cell targets by I-A+ accesory cells. J. Immunol., 134:2867-2871 (1985).
100. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel: Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (London), 362:758-761 (1993).
101. Mosmann,T. R. andR. L. Coffman: Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immunol., 46:111-147 (1989).
102. Mukherji, B. and N. G. Chakraborty: Immunobiology and immunotherapy of melanoma. Curr. Opin. Oncol., 7:175-184 (1995).
103. Nakagomi, H., M. Peterson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellsted, J. Taupin, E. Vivier, P. Ander- son, and R. Kiessling: Decreased expression of the signal-transducing ζ chain in tumor-infiltrating T cells and NK cells of patients with colorectal carcinomas. Cancer Res., 53:5610-5612 (1993).
104. Nelson, D. S. and M. Nelson: Evasion of host defenses by tumor. Immunol. Cell Biol., 65:287 (1987).
105. North, R. J.: Cyclophosphami de-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med., 155:1063-1074 (1982).
106. Nossal, G. J. V.: Negative selection of lymphocytes. Cell, 76:229-239 (1994).
107. Ohasni, P. S., S. Oehen, K. Burki, H. Pircher, C. T. Ohashi, B. Odermatt, B. Malissen, R. M. Zinkernagel, and H. Hengartner: Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell, 65:305-317 (1991).
108. Oldstone, M. B., M. Nerenberg, P. Southern, J. Price, and H. Lewicki: Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-serf (virus) immune response. Cell, 65:319-331 (1991).
109. Ostrand-Rosenberg, S.: Tumor immunotherapy: the tumor cell as antigen-presenting cell. Curr. Opin. Immunol., 6:722-727 (1994).
110. Owen, R. D.: Immunogenetic consequences of vascular anastomoses between bovine twins. Science, 102:400-401 (1945).
111. Pardoll, D. M.: New strategies for enhancing the immunogenicity of tumors. Curr. Opin. Immunol., 5:719-725 (1993).
112. Pardoll, D. M.: Cancer vaccines: a road map for the next decade. Curr. Opin. Immunol., 8:619-621 (1996).
113. Paterson, I. and G. Ikonomidis: Recombinant Listeria monocytogenes cancer vaccines. Curr. Opin. Immunol., 8:664-669 (1996).
114. Paul, R. D., A. Ghaffar, M. M. Sigel, V. Charyulu, and D. M. Lopez: Splenic alterations during mammary tumorigenesis: diverse effects on different immune parameters. Anticancer Res., 1:63-70 (1981).
115. Perez, V. L., L. Van Parijs, A. Biuckians, X. Zheng, T. B. Strom, and A. K. Abbas: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity, 6:411-417 (1997).
116. Perrin, P. J., J. H. Maldonado, T. A. Davis, C. H. June, and M. K. Racke: CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol., 157:1333-1336 (1996).
117. Quill, H. and R. H. Schwartz: Stimulation of normal inducer T cell clones with antigen presented by purified la molecules in planar lipid membranes: specific induction of a long-lived state of proliferation nonresponsiveness. J. Immunol., 138:3704-3712 (1987).
118. fyn. J. Immunol., 149:2887-2893 (1992).
119. + T lymphocytes on immunizing Mls-1b with Mis-1a expressing cells. Nature (London), 339:541-543 (1989).
120. Reiser, H., G. J. Freeman, Z. Razi-Wolf, C. D. Gimmi, B. Benacerraf, and L. M. Nadler: Murine B7 antigen provides an efficient costimulatory signal for activation of mutine T lymphocytes via the T-cell receptor/CD3 complex. Proc. Natl. Acad. Sci. U.S.A., 89:271-275 (1992).
121. Robbins, P. F. and Y. Kawakami: Human tumor antigens recognized by T cells. Curr. Opin. Immunol., 8:628-636 (1996).
122. Rocha, B., C. Tanchot, and H. von Boehmer: Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J. Exp. Med., 177:1517-1521 (1993).
123. Rocken, M., J. F. Urban, and E. M. Shevach: Infection breaks T-cell tolerance. Nature, 359:79-82 (1992).
124. Rogge, L., L. Barberis-Maino, M. Biffi, N. Passini, D. H. Presky, U. Gubler, and F. Sinigaglia: Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med., 185:825-831 (1997).
125. Rouvier, E., M-F. Luciani, and P. Golstein: Fas involvement in Ca-independent T-cell-mediated cytotoxicity. J. Exp. Med., 177:195-200 (1993).
126. Russell, J. H.: Activation-induced death of mature T cells in the regulation of immune responses. Curr. Opin. Immunol., 7:382-388 (1995).
127. Russell, J. H., B. Rush, C. Weaver, and R. Wang: Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. U.S.A., 90:4409-4413 (1993).
128. Sadick, M. D., F. P. Heinzel, B. J. Holaday, R. T. Pu, R. S. Dawkins, and R. M. Locksley: Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody: evidence for a T cell-dependent, interferon γ-independent mechanism. J. Exp. Med., 171:115-127 (1990).
129. + T cells. J. Immunol., 139:1303-1309 (1987).
130. Sarvetnick, N., J. Shizuru, D. Liggitt, L. Martin, B. McIntyre, A. Gregory, T. Parslow, and T. Stewart: Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ. Nature, 346:844-847 (1990).
131. Schild, H., O. Rotzschke, H. Kaibacher, and H-G. Rammensee: Limit of T cell to self proteins by peptide presentation. Science, 247:1587-1589 (1990).
132. Schonrich, G., U. Kalinke, F. Momburg, M. Malissen, A. M. Schmitt-Verhulst, B. Malissen, G. J. Hammerling, and B. Arnold: Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell, 65:293-310 (1991).
133. Schultze, J. L., V. A. Boussiotis, D. Dorfman, A. A. Cardoso, M. J. Seamon, H. M. Afonso, J. G. Gribben, and L. M. Nadler: Absence of anti-follicular lymphoma (FL) specific T cell mediated immunity is associated with significant reduction of T cell receptor ζ chain and granzyme B expression. Blood, 86:272a (1995).
134. Schwartz, R. H.: T cell clonal anergy. Curr. Opin. Immunol., 9:351-357 (1997).
135. Schweitzer, A. N., F. Borriello, R. C. K. Wong, A. K. Abbas, and A. H. Sharpe: Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86. J. Immunol., 158:2713-2722 (1997).
136. Scott, B., H. Bluthmann, H. S. Teh, and H. von Boehmer: The generation of mature T cells requires interaction of the αβ T-cell receptor with major histocompatibility antigens. Nature, 338:591-593 (1989).
137. + T cells. Ann. Rev. Immunol., 12:635-673 (1994).
138. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kundig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak: Differential T cell costimulatory requirements in CD28-deficient mice. Science, 261:609-612 (1993).
139. Simons, J. W., E. M. Jafee, C. Weber, H. I. Levitsky, W. G. Nelson, M. A. Carducci, A. J. Lazenby, L. Cohen, C. C. Finn, S. L. Clift, K. M. Hauda, A. H. Owens, S. Piantadosi, G. Dranoff, R. C. Mulligan, D. M. Pardoll, and F. F. Marshall: Bioactivity of human GM-CSF gene transfer in autologous-irradiated renal cell carcinoma vaccines. Cancer Res., 57:1537-1546 (1997).
140. Singer, G. G. and A. K. Abbas: The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity, 1:365-371 (1994).
141. Sinha, S. A., M. T. Lopez, and H. O. McDevitt: Autoimmune diseases: the failure of self-tolerance. Science, 248:1380-1388 (1990).
142. Sotomayor, E. M., Y-X. Fu, M. Lopez-Cepero, L. Herbert, J. J. Jimenez, C. Albarracin, and D. M. Lopez: Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor. J. Immunol., 147:2816-2823 (1991).
143. Sotomayor, E. M., X-F. Cheng, Y-X. Fu, A. Hawkins, C. Calderon-Higginson, and D. M. Lopez: Impaired activation of tumoricidal function in macrophages from mammary tumor bearers: the role of IFN-gamma. Int. J. Oncol., 3:719-727 (1993).
144. a. J. Exp. Med., 170:595-600 (1989).
145. Strand, S., W. J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S. M. Mariani, W. Stremmel, P. H. Krammer, and P. R. Galle: Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med., 2:1361-1366 (1996).
146. Streilein, J. W.: Unraveling immune privilege. Science, 270:1158-1159(1995).
147. Szabo, S. J., A. S. Dighe, U. Gubler, and K. M. Murphy: Regulation of the interleukin (IL)-12R β2 subunit ex- pression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med., 185:817-824 (1997).
148. Takashi, R., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata: Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell, 76:969-976 (1994).
149. Takasugi, M., A. Ramseyer, and J. Tagasuki: Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res., 37:413-418 (1977).
150. Tivol, E. A., F. Borriello, A. N. Schweiter, W. P. Lynch, J. A. Bluestone, and A. H. Sharpe: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 3:541-547 (1995).
151. + T cells by B7-transfected melanoma cells. Science, 259:368-370 (1993).
152. Towsend, S. E., F. W. Su, J. M. Atherton, and J. P. Allison: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res., 54:5420-5423 (1994).
153. Traut, B. C., C. Klas, A. M. J. Peters, S. Matzku, P. Moller, W. Falk, K-M. Debatin, and P. H. Krammer: Monoclonal antibody-mediated tumor regresion by induction of apoptosis. Science, 245:301-301 (1989).
154. van Parijs, L.A., A. Ibraghimov, and A. K. Abbas: The role of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity, 4:321-328 (1996).
155. Vignaux, F. and P. Golstein: Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway? Eur. J. Immunol., 24:923-927 (1994).
156. Von Boehmer, H.: Positive selection of lymphocytes. Cell, 76:219-228 (1994).
157. Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone: CTLA-4 can function as a negative regulator of activation. Immunity, 1:405-413 (1994).
158. Watanabe-Kukunaga, R., C. I. Branna, N. G. Copeland, N. A. Jenkins, and S. Nagata: Lymphoproliferation disorders in mice explained by defects in Fas antigen that mediates apoptosis. Nature, 356:314-317 (1992).
159. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, and T. W. Mak: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science, 270:985-988 (1995).
160. Webb, S. C., C. Morris, and J. Sprent: Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell, 63:1249-1256 (1990).
161. Weigle, W. O.: Immunological unresponsiveness. Adv. Immunol., 16:61-122
162. Wraith, D. C., H. O. McDevitt, L. Steinman, and H. Acha-Orbea: T cell recognition as the target for immune intervention in autoimmune disease. Cell, 57:709-715 (1989).
163. Wu, T. C., A. Y. Huang, E. M. Jaffee, H. I. Levitsky, and D. M. Pardoll: A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med., 182:1415-1421 (1995).
164. Yang, G., K. E. Hellstrom, I. Hellstrom, and L. Chen: Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol., 154:2794-2800 (1995).
165. Yang, Y. and J. M. Wilson: CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science, 273:1862-1864 (1996).
166. Yonehara, S., A. Ishii, and M. Yonehara: A cell-killing monoclonal antibody (anti-Fas) to a cellular surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169:1747-1756 (1989).
167. Young, R. C.: Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am. J. Med., 52:63-72 (1972).